Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01666951 · ClinicalTrials.gov registry record · Phase 2
Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant
A Phase 2 study, sponsored by Veloxis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
NCT01666951 is a Phase 2 study that has completed, run by Veloxis Pharmaceuticals. The registered enrollment target is 36 participants.
The verdict
NCT01666951, a Phase 2 study, has completed, sponsored by Veloxis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
Interventions
- DRUG Prograf
- DRUG LCP-Tacro tablets
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2012-11 |
| Est. Completion | 2013-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01666951
The ClinicalTrials.gov registry entry for NCT01666951 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Veloxis Pharmaceuticals, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Prograf is the first listed.
NCT01666951 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01666951 about?
NCT01666951 is a clinical study titled "Multicenter, Prospective, Rand, PK Study of LCP-Tacro™ Compared to Prograf® Capsules in De Novo Adult Kidney Transplant". The purpose of this study is to evaluate the pharmacokinetics of LCP-Tacro tablets administered once-daily compared to Prograf capsules administered twice-daily after kidney transplantation.
What is the current status of trial NCT01666951?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2012-11. Estimated completion is 2013-05.
What interventions are being tested in trial NCT01666951?
The interventions under investigation include: Prograf (DRUG), LCP-Tacro tablets (DRUG).
Who is sponsoring clinical trial NCT01666951?
This trial is sponsored by Veloxis Pharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.